<p>根据最近向证券交易委员会（SEC）提交的文件，Sequoia Financial Advisors LLC 在第三季度将其在礼来公司（NYSE:LLY - 免费报告）股票中的持仓增加了 4.3%。该基金在此期间购买了 6,021 股后，持有 146,222 股该公司的股票。在最近的报告期结束时，Sequoia Financial Advisors LLC 在礼来公司的持股价值为 111,568,000 美元。</p>
<p>获取 <strong>礼来公司</strong> 的提醒：</p>
<ul>
<li>一项长期投资者不应忽视的新 IPO</li>
</ul>
<p>其他几家大型投资者最近也增加或减少了在该公司的股份。住友三井金融集团在第二季度购买了礼来公司的新股份，价值约为 27,000 美元。Evolution Wealth Management Inc.在第二季度购买了礼来公司的新股份，价值约为 29,000 美元。Steph &amp; Co.在第三季度将其在礼来公司的股份增加了 290.0%。Steph &amp; Co.现在持有 39 股该公司的股票，价值 30,000 美元，此前在上个季度又购买了 29 股。Financial Gravity Companies Inc.在第二季度购买了礼来公司的新股份，价值约为 31,000 美元。最后，Bare Financial Services Inc 在第二季度将其在礼来公司的持股增加了 263.6%。Bare Financial Services Inc 现在持有 40 股该公司的股票，价值 31,000 美元，此前在此期间又收购了 29 股。对冲基金和其他机构投资者持有该公司 82.53% 的股票。</p>
<h2>礼来公司新闻汇总</h2>
<p>以下是本周影响礼来公司的主要新闻：</p>
<ul>
<li>积极情绪：与 Nvidia 的合作——礼来与 Nvidia 宣布联合投资 10 亿美元建立和装备一个 AI 驱动的研究设施，标志着长期研发加速和药物发现潜在生产力提升。Nvidia 与礼来合作建立 10 亿美元实验室。投资者需要了解的内容。</li>
<li>积极情绪：管线进展——礼来报告在中国完成了一项新口服候选药物的第一阶段研究，推进了其口服 GLP1 管线，并降低了未来在美国以外的监管风险。礼来在中国完成第一阶段研究，悄然推进新口服候选药物。</li>
<li>积极情绪：口服和肿瘤研发信号——关于 olomorasib 胶囊研究和日本第一阶段组合试验的更新显示，除了当前的 GLP-1 系列外，管线势头稳健且多样化。礼来的 Olomorasib 胶囊研究为投资者信号稳定的管线进展，礼来通过日本第一阶段组合研究推进下一波肥胖管线。</li>
<li>积极情绪：分析师支持和战略重点——摩根大通强调心血管 Lp(a) 项目，分析师（如 Jefferies）维持乐观目标，强化了超越肥胖药物的增长叙事。摩根大通：礼来强调 Lp(a) 药物作为心血管增长重点。</li>
<li>中性情绪：财报前的势头——市场指标显示，在即将发布的财报前，强劲的势头和高分析师关注度，这可能会放大日内波动，但也增加了对财报的依赖。礼来股票接近高点，随着财报前的势头信号。</li>
<li>中性情绪：投资者评论——几篇评论文章认为，考虑到礼来的基本面，最近的下跌是一个买入机会；这些有助于情绪，但并不是新的催化剂。是否在 LLY 股票中买入？</li>
<li>消极情绪：FDA 对口服肥胖药物 Orforglipron 的延迟——报道称，监管机构将其决定推迟到四月，这给股票施加了压力，延长了竞争对手的优势并推迟了潜在销售。礼来股票在 FDA reportedly 推迟肥胖药物裁决后下跌。</li>
<li>消极情绪：反垄断/竞争诉讼——一家复合药房起诉礼来和诺和诺德，声称协调努力限制复合替代品；诉讼风险增加了监管/法律不确定性。礼来和诺和诺德因复合药房对 GLP-1 药物的主导地位而被起诉。</li>
</ul>
<h2>分析师设定新目标价</h2>
<ul>
<li>礼来股票因 Ventyx 交易而反弹，缓解了对 Wegovy 的担忧</li>
</ul>
<p>多家研究公司最近对 LLY 发表了评论。国家银行在 12 月 1 日的报告中将礼来公司的目标价设定为 1,286.00 美元。大和资本市场在 12 月 16 日的研究报告中将礼来公司的目标价设定为 1,230.00 美元，并给予该股票 “买入” 评级。Zacks Research 在 1 月 1 日的研究报告中将礼来公司的评级从 “持有” 上调至 “强力买入”。Wolfe Research 在 12 月 3 日的研究报告中将礼来公司的目标价从 1,050.00 美元提高到 1,250.00 美元，并给予该公司 “跑赢大盘” 评级。最后，富国银行在 12 月 10 日的报告中将礼来公司的目标价从 1,100.00 美元提高到 1,200.00 美元，并给予该股票 “超配” 评级。五位研究分析师对该股票给予了强力买入评级，十九位给予了买入评级，四位给予了持有评级。根据 MarketBeat 的数据，该公司的平均评级为 “买入”，平均目标价为 1,174.70 美元。</p>
<p><strong>查看我们关于礼来公司的最新报告</strong></p>
<h2>礼来公司的股票上涨 0.5%</h2>
<ul>
<li>该 ETF 证明医疗保健反弹是真实的</li>
</ul>
<p>礼来公司的股票在周五开盘价为 1,038.26 美元。礼来公司的 1 年最低价为 623.78 美元，1 年最高价为 1,133.95 美元。该公司的市值为 9815.5 亿美元，市盈率为 50.80，市盈率/增长比率为 0.75，贝塔值为 0.35。该公司的债务与股本比率为 1.71，流动比率为 1.55，速动比率为 1.24。该公司的 50 日简单移动平均线为 1,051.34 美元，200 日简单移动平均线为 870.84 美元。</p>
<p>礼来公司（NYSE:LLY - 获取免费报告）最近于 10 月 30 日发布了季度财报。该公司报告本季度每股收益为 7.02 美元，超出分析师一致预期的 6.42 美元，超出幅度为 0.60 美元。该公司本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。与去年同期相比，该公司的季度收入增长了 53.9%。在去年同期，该公司每股收益为 1.18 美元。礼来公司已将 2025 财年的指引设定为每股收益 23.000-23.700 美元。卖方分析师预测，礼来公司在当前财年将发布每股收益 23.48 美元。</p>
<h2>礼来公司增加股息</h2>
<p>该公司最近宣布了一项季度股息，将于 3 月 10 日（星期二）支付。记录在案的股东将在 2 月 13 日（星期五）获得每股 1.73 美元的股息。除息日期为 2 月 13 日（星期五）。这比礼来公司之前的季度股息 1.50 美元有所增加。这相当于年化股息 6.92 美元，收益率为 0.7%。礼来公司的股息支付比率（DPR）为 29.35%。</p>
<h2>关于礼来公司</h2>
<p>（免费报告）</p>
<p>礼来公司（NYSE: LLY）是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来在北美、欧洲、亚洲及其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票超过礼来公司</li>
<li>埃隆将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护您的财富</li>
<li>紧急：特朗普刚刚引发了人工智能的最大颠覆</li>
<li>华尔街警报：买入 AES</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
<p>在考虑投资礼来公司之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而礼来公司并不在名单上。</p>
<p>虽然礼来公司目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

礼来

<p>Sequoia Financial Advisors LLC 在第三季度将其在礼来公司（NYSE: LLY）的持股增加了 4.3%，额外购买了 6,021 股，总持股达到 146,222 股，价值 1.1157 亿美元。其他投资者也调整了他们的持仓，包括住友三井和 Evolution Wealth Management 等公司显著的新投资。礼来的最新进展包括与 Nvidia 合作建立一个人工智能研究设施，以及在其药物研发管线上的进展，尽管面临 FDA 对一款减肥药的延迟和持续的诉讼风险</p>

<p>Sequoia Financial Advisors LLC grew its position in shares of Eli Lilly and Company (NYSE:LLY - Free Report) by 4.3% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 146,222 shares of the company's stock after buying an additional 6,021 shares during the period. Sequoia Financial Advisors LLC's holdings in Eli Lilly and Company were worth $111,568,000 at the end of the most recent reporting period.</p>
<div class="lb-trans"><p>根据最近向证券交易委员会（SEC）提交的文件，Sequoia Financial Advisors LLC 在第三季度将其在礼来公司（NYSE:LLY - 免费报告）股票中的持仓增加了 4.3%。该基金在此期间购买了 6,021 股后，持有 146,222 股该公司的股票。在最近的报告期结束时，Sequoia Financial Advisors LLC 在礼来公司的持股价值为 111,568,000 美元。</p>
</div><p>Get <strong>Eli Lilly and Company</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>礼来公司</strong> 的提醒：</p>
</div><ul>
<li>A Fresh IPO That Long-Term Investors Shouldn’t Ignore</li>
</ul>
<div class="lb-trans"><ul>
<li>一项长期投资者不应忽视的新 IPO</li>
</ul>
</div><p>Several other large investors also recently added to or reduced their stakes in the company. Sumitomo Mitsui Financial Group Inc. bought a new position in Eli Lilly and Company during the second quarter worth about $27,000. Evolution Wealth Management Inc. purchased a new stake in shares of Eli Lilly and Company during the 2nd quarter valued at approximately $29,000. Steph &amp; Co. lifted its stake in shares of Eli Lilly and Company by 290.0% during the 3rd quarter. Steph &amp; Co. now owns 39 shares of the company's stock valued at $30,000 after buying an additional 29 shares in the last quarter. Financial Gravity Companies Inc. purchased a new position in Eli Lilly and Company in the 2nd quarter valued at approximately $31,000. Finally, Bare Financial Services Inc raised its holdings in Eli Lilly and Company by 263.6% during the 2nd quarter. Bare Financial Services Inc now owns 40 shares of the company's stock valued at $31,000 after acquiring an additional 29 shares during the period. Hedge funds and other institutional investors own 82.53% of the company's stock.</p>
<div class="lb-trans"><p>其他几家大型投资者最近也增加或减少了在该公司的股份。住友三井金融集团在第二季度购买了礼来公司的新股份，价值约为 27,000 美元。Evolution Wealth Management Inc.在第二季度购买了礼来公司的新股份，价值约为 29,000 美元。Steph &amp; Co.在第三季度将其在礼来公司的股份增加了 290.0%。Steph &amp; Co.现在持有 39 股该公司的股票，价值 30,000 美元，此前在上个季度又购买了 29 股。Financial Gravity Companies Inc.在第二季度购买了礼来公司的新股份，价值约为 31,000 美元。最后，Bare Financial Services Inc 在第二季度将其在礼来公司的持股增加了 263.6%。Bare Financial Services Inc 现在持有 40 股该公司的股票，价值 31,000 美元，此前在此期间又收购了 29 股。对冲基金和其他机构投资者持有该公司 82.53% 的股票。</p>
</div><h2>Eli Lilly and Company News Roundup</h2>
<div class="lb-trans"><h2>礼来公司新闻汇总</h2>
</div><p>Here are the key news stories impacting Eli Lilly and Company this week:</p>
<div class="lb-trans"><p>以下是本周影响礼来公司的主要新闻：</p>
</div><ul>
<li>Positive Sentiment: Nvidia partnership — Lilly and Nvidia announced a joint $1 billion lab to build and equip an AI-enabled research facility, signaling long-term R&amp;D acceleration and potential productivity gains for drug discovery. Nvidia and Eli Lilly Are Partnering on a $1 Billion Lab. Here's What Investors Need to Know.</li>
<li>Positive Sentiment: Pipeline progress — Lilly reported completion of a Phase 1 study in China for a new oral candidate, advancing its oral-GLP1 pipeline and de‑risking future regulatory steps outside the U.S. Eli Lilly Quietly Advances New Oral Candidate With Completion of Phase 1 Study in China</li>
<li>Positive Sentiment: Oral and oncology R&amp;D signals — Updates on olomorasib capsule study and a Japanese Phase 1 combo trial for next‑wave obesity drugs show steady, diversified pipeline momentum beyond current GLP‑1 franchises. Eli Lilly’s Olomorasib Capsule Study Signals Steady Pipeline Progress for InvestorsLilly Advances Next-Wave Obesity Pipeline With Japanese Phase 1 Combo Study</li>
<li>Positive Sentiment: Analyst backing and strategic focus — JPMorgan highlights cardiovascular Lp(a) programs and analysts (e.g., Jefferies) maintain bullish targets, reinforcing the growth narrative beyond obesity drugs. JPM26: Eli Lilly highlights Lp(a) drugs as cardiovascular growth focus</li>
<li>Neutral Sentiment: Pre-earnings momentum — Market indicators show strong momentum and high analyst interest ahead of upcoming earnings, which can amplify intraday moves but increases dependence on the print. Eli Lilly Shares Near Highs As Score Flags Momentum Ahead Of Earnings</li>
<li>Neutral Sentiment: Investor commentary — Several opinion pieces argue the recent dip is a buying opportunity given Lilly’s fundamentals; these help sentiment but are not new catalysts. Buy The Dip In LLY Stock?</li>
<li>Negative Sentiment: FDA delay on oral obesity pill Orforglipron — Reports the regulator pushed its decision to April have pressured the stock by extending competitor advantage and delaying potential sales. LLY Stock Falls After FDA Reportedly Delays Obesity Drug Ruling</li>
<li>Negative Sentiment: Antitrust/competition litigation — A compounding pharmacy sued Lilly and Novo Nordisk claiming coordinated efforts to limit compounding substitutes; litigation risk adds regulatory/legal uncertainty. Lilly, Novo sued over GLP‑1 drug dominance by compounding pharmacy</li>
</ul>
<div class="lb-trans"><ul>
<li>积极情绪：与 Nvidia 的合作——礼来与 Nvidia 宣布联合投资 10 亿美元建立和装备一个 AI 驱动的研究设施，标志着长期研发加速和药物发现潜在生产力提升。Nvidia 与礼来合作建立 10 亿美元实验室。投资者需要了解的内容。</li>
<li>积极情绪：管线进展——礼来报告在中国完成了一项新口服候选药物的第一阶段研究，推进了其口服 GLP1 管线，并降低了未来在美国以外的监管风险。礼来在中国完成第一阶段研究，悄然推进新口服候选药物。</li>
<li>积极情绪：口服和肿瘤研发信号——关于 olomorasib 胶囊研究和日本第一阶段组合试验的更新显示，除了当前的 GLP-1 系列外，管线势头稳健且多样化。礼来的 Olomorasib 胶囊研究为投资者信号稳定的管线进展，礼来通过日本第一阶段组合研究推进下一波肥胖管线。</li>
<li>积极情绪：分析师支持和战略重点——摩根大通强调心血管 Lp(a) 项目，分析师（如 Jefferies）维持乐观目标，强化了超越肥胖药物的增长叙事。摩根大通：礼来强调 Lp(a) 药物作为心血管增长重点。</li>
<li>中性情绪：财报前的势头——市场指标显示，在即将发布的财报前，强劲的势头和高分析师关注度，这可能会放大日内波动，但也增加了对财报的依赖。礼来股票接近高点，随着财报前的势头信号。</li>
<li>中性情绪：投资者评论——几篇评论文章认为，考虑到礼来的基本面，最近的下跌是一个买入机会；这些有助于情绪，但并不是新的催化剂。是否在 LLY 股票中买入？</li>
<li>消极情绪：FDA 对口服肥胖药物 Orforglipron 的延迟——报道称，监管机构将其决定推迟到四月，这给股票施加了压力，延长了竞争对手的优势并推迟了潜在销售。礼来股票在 FDA reportedly 推迟肥胖药物裁决后下跌。</li>
<li>消极情绪：反垄断/竞争诉讼——一家复合药房起诉礼来和诺和诺德，声称协调努力限制复合替代品；诉讼风险增加了监管/法律不确定性。礼来和诺和诺德因复合药房对 GLP-1 药物的主导地位而被起诉。</li>
</ul>
</div><h2>Analysts Set New Price Targets</h2>
<div class="lb-trans"><h2>分析师设定新目标价</h2>
</div><ul>
<li>Eli Lilly Stock Rallies as Ventyx Deal Calms Wegovy Concerns</li>
</ul>
<div class="lb-trans"><ul>
<li>礼来股票因 Ventyx 交易而反弹，缓解了对 Wegovy 的担忧</li>
</ul>
</div><p>A number of research firms have recently commented on LLY. National Bankshares set a $1,286.00 price target on Eli Lilly and Company in a report on Monday, December 1st. Daiwa Capital Markets set a $1,230.00 target price on Eli Lilly and Company and gave the stock a &#34;buy&#34; rating in a research note on Tuesday, December 16th. Zacks Research upgraded Eli Lilly and Company from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Thursday, January 1st. Wolfe Research boosted their price objective on shares of Eli Lilly and Company from $1,050.00 to $1,250.00 and gave the company an &#34;outperform&#34; rating in a research note on Wednesday, December 3rd. Finally, Wells Fargo &amp; Company upped their target price on shares of Eli Lilly and Company from $1,100.00 to $1,200.00 and gave the stock an &#34;overweight&#34; rating in a report on Wednesday, December 10th. Five research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and four have issued a Hold rating to the company's stock. Based on data from MarketBeat, the company has an average rating of &#34;Buy&#34; and an average price target of $1,174.70.</p>
<div class="lb-trans"><p>多家研究公司最近对 LLY 发表了评论。国家银行在 12 月 1 日的报告中将礼来公司的目标价设定为 1,286.00 美元。大和资本市场在 12 月 16 日的研究报告中将礼来公司的目标价设定为 1,230.00 美元，并给予该股票 “买入” 评级。Zacks Research 在 1 月 1 日的研究报告中将礼来公司的评级从 “持有” 上调至 “强力买入”。Wolfe Research 在 12 月 3 日的研究报告中将礼来公司的目标价从 1,050.00 美元提高到 1,250.00 美元，并给予该公司 “跑赢大盘” 评级。最后，富国银行在 12 月 10 日的报告中将礼来公司的目标价从 1,100.00 美元提高到 1,200.00 美元，并给予该股票 “超配” 评级。五位研究分析师对该股票给予了强力买入评级，十九位给予了买入评级，四位给予了持有评级。根据 MarketBeat 的数据，该公司的平均评级为 “买入”，平均目标价为 1,174.70 美元。</p>
</div><p><strong>View Our Latest Report on Eli Lilly and Company</strong></p>
<div class="lb-trans"><p><strong>查看我们关于礼来公司的最新报告</strong></p>
</div><h2>Eli Lilly and Company Trading Up 0.5%</h2>
<div class="lb-trans"><h2>礼来公司的股票上涨 0.5%</h2>
</div><ul>
<li>This ETF Is Proof That the Healthcare Rebound Is Real</li>
</ul>
<div class="lb-trans"><ul>
<li>该 ETF 证明医疗保健反弹是真实的</li>
</ul>
</div><p>Shares of LLY opened at $1,038.26 on Friday. Eli Lilly and Company has a 1-year low of $623.78 and a 1-year high of $1,133.95. The company has a market capitalization of $981.55 billion, a P/E ratio of 50.80, a P/E/G ratio of 0.75 and a beta of 0.35. The company has a debt-to-equity ratio of 1.71, a current ratio of 1.55 and a quick ratio of 1.24. The firm's 50 day simple moving average is $1,051.34 and its 200 day simple moving average is $870.84.</p>
<div class="lb-trans"><p>礼来公司的股票在周五开盘价为 1,038.26 美元。礼来公司的 1 年最低价为 623.78 美元，1 年最高价为 1,133.95 美元。该公司的市值为 9815.5 亿美元，市盈率为 50.80，市盈率/增长比率为 0.75，贝塔值为 0.35。该公司的债务与股本比率为 1.71，流动比率为 1.55，速动比率为 1.24。该公司的 50 日简单移动平均线为 1,051.34 美元，200 日简单移动平均线为 870.84 美元。</p>
</div><p>Eli Lilly and Company (NYSE:LLY - Get Free Report) last issued its quarterly earnings results on Thursday, October 30th. The company reported $7.02 EPS for the quarter, topping analysts' consensus estimates of $6.42 by $0.60. The firm had revenue of $17.60 billion for the quarter, compared to analyst estimates of $16.09 billion. Eli Lilly and Company had a net margin of 30.99% and a return on equity of 109.52%. The business's revenue for the quarter was up 53.9% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $1.18 EPS. Eli Lilly and Company has set its FY 2025 guidance at 23.000-23.700 EPS. Sell-side analysts forecast that Eli Lilly and Company will post 23.48 earnings per share for the current fiscal year.</p>
<div class="lb-trans"><p>礼来公司（NYSE:LLY - 获取免费报告）最近于 10 月 30 日发布了季度财报。该公司报告本季度每股收益为 7.02 美元，超出分析师一致预期的 6.42 美元，超出幅度为 0.60 美元。该公司本季度的收入为 176 亿美元，而分析师预期为 160.9 亿美元。礼来公司的净利润率为 30.99%，股本回报率为 109.52%。与去年同期相比，该公司的季度收入增长了 53.9%。在去年同期，该公司每股收益为 1.18 美元。礼来公司已将 2025 财年的指引设定为每股收益 23.000-23.700 美元。卖方分析师预测，礼来公司在当前财年将发布每股收益 23.48 美元。</p>
</div><h2>Eli Lilly and Company Increases Dividend</h2>
<div class="lb-trans"><h2>礼来公司增加股息</h2>
</div><p>The company also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Friday, February 13th will be given a dividend of $1.73 per share. The ex-dividend date is Friday, February 13th. This is a positive change from Eli Lilly and Company's previous quarterly dividend of $1.50. This represents a $6.92 dividend on an annualized basis and a yield of 0.7%. Eli Lilly and Company's dividend payout ratio (DPR) is 29.35%.</p>
<div class="lb-trans"><p>该公司最近宣布了一项季度股息，将于 3 月 10 日（星期二）支付。记录在案的股东将在 2 月 13 日（星期五）获得每股 1.73 美元的股息。除息日期为 2 月 13 日（星期五）。这比礼来公司之前的季度股息 1.50 美元有所增加。这相当于年化股息 6.92 美元，收益率为 0.7%。礼来公司的股息支付比率（DPR）为 29.35%。</p>
</div><h2>About Eli Lilly and Company</h2>
<div class="lb-trans"><h2>关于礼来公司</h2>
</div><p>(Free Report)</p>
<div class="lb-trans"><p>（免费报告）</p>
</div><p>Eli Lilly and Company NYSE: LLY is a global pharmaceutical company founded in 1876 and headquartered in Indianapolis, Indiana. The company researches, develops, manufactures and commercializes a broad range of medicines and therapies for patients worldwide. Eli Lilly maintains operations and commercial presence across North America, Europe, Asia and other regions, serving both developed and emerging markets. The company has been led in recent years by President and Chief Executive Officer David A.</p>
<div class="lb-trans"><p>礼来公司（NYSE: LLY）是一家成立于 1876 年的全球制药公司，总部位于印第安纳州印第安纳波利斯。该公司研究、开发、生产和商业化广泛的药物和疗法，服务于全球患者。礼来在北美、欧洲、亚洲及其他地区开展业务并拥有商业存在，服务于发达市场和新兴市场。近年来，该公司由总裁兼首席执行官 David A.领导。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Eli Lilly and Company</li>
<li>Elon Taking SpaceX Public! $100 Pre-IPO Opportunity!</li>
<li>Do not delete, read immediately</li>
<li>How a Family Trust May Be Able To Help Preserve Your Wealth</li>
<li>URGENT: Trump Just Triggered AI’s Biggest Disruption Yet</li>
<li>Wall Street Alert: Buy AES</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过礼来公司</li>
<li>埃隆将 SpaceX 上市！100 美元的首次公开募股机会！</li>
<li>请勿删除，立即阅读</li>
<li>家族信托如何帮助保护您的财富</li>
<li>紧急：特朗普刚刚引发了人工智能的最大颠覆</li>
<li>华尔街警报：买入 AES</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/SECFilingChart.ashx/query-UHJlZml4PU5ZU0UmU3ltYm9sPUxMWQ" alt="" original-src="https://www.marketbeat.com/scripts/SECFilingChart.ashx?Prefix=NYSE&amp;Symbol=LLY"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。如对本故事有任何问题或意见，请发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Eli Lilly and Company Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1000 美元在礼来公司吗？</h2>
</div><p>Before you consider Eli Lilly and Company, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑投资礼来公司之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Eli Lilly and Company wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只顶级分析师悄悄建议客户现在购买的股票，而礼来公司并不在名单上。</p>
</div><p>While Eli Lilly and Company currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然礼来公司目前在分析师中获得了买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

红杉金融顾问有限责任公司购入了礼来公司 6,021 股股票 $LLY